ClinicalTrials.gg
CompletedNCT04190147Updated May 6, 2022

Eye and Growth in Adolescents Born Moderate-to-late Preterm

An observational study in Preterm Birth, Visual Impairment and Eye Abnormalities, sponsored by Vastra Gotaland Region. Completed at 1 site in Sweden. Open to participants aged 15 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Vastra Gotaland Region · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
15 Years to 17 Years
Sex
All
01

Study summary

During recent years, the interest in studying the risks of being born moderate-to-late preterm (MLP), defined as birth between gestational week 32 to 36, has increased. Today the investigators know that morbidity and mortality are significantly higher in these individuals compared to individuals born full-term. However, few studies have focused on the development of the eye in MLP individuals. The purpose of the study is to evaluate eye morphology and visual function in relation to growth, metabolism, blood pressure, neuropsychiatric factors, and quality of life in adolescents born MLP. The results of the examinations will be compared to an age-matched control group. The study will evaluate the structural, functional, and metabolic aspects of the eye with the hypothesis that early eye abnormalities may detect the risk of developing metabolic and cardiovascular diseases.

02

Conditions studied

  • Preterm Birth
  • Visual Impairment
  • Eye Abnormalities

Keywords

  • Moderate-to-late preterm
03

In context

Premature Birth

2,615 studies on the registry are indexed under Premature Birth; 507 are open to participants now.

This study's enrollment of 100 is below the median of 115 across 798 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Vastra Gotaland Region is the lead sponsor of 272 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Year 2002 to 2004, 247 children born moderate-to-late preterm i Gothenburg, Sweden, were enrolled in a prospective, longitudinal and population-based cohort study. These children will be asked to participate in the present follow-up study 15 years later. The age-matched control group born full-term will be recruited from schools in Gothenburg.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Born moderate-to-late preterm.
  • Born in Gothenburg, Sweden.
  • Born between years 2002 and 2004.

Exclusion criteria

Exclusion Criteria:

  • Chromosomal abnormalities.
  • Syndromes.
  • Severe malformations.
  • Asphyxia.
  • Language difficulties.
  • Psychosocial problems at birth.
  • Severe maternal illness.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (actual)
Patient registry
No

Groups and cohorts

  • Moderate-to-late preterm group

    Other: Structural, functional and metabolic eye examinations

  • Full-term group

    Other: Structural, functional and metabolic eye examinations

Interventions

  • OtherStructural, functional and metabolic eye examinations

    Structural, functional and metabolic eye examinations

06

What researchers measure

Primary outcomes

  1. Optic disc area.

    Optic disc area measured with Optical coherence tomography (OCT, Topcon).

    Time frame: Through study completion, an average of 6 months

  2. Visual acuity.

    Visual acuity measured with Early Treatment Diabetic Retinopathy Study (ETDRS) scores.

    Time frame: Through study completion, an average of 6 months.

  3. Blood pressure.

    Systolic and diastolic blood pressure measured with blood pressure cuffs.

    Time frame: Through study completion, an average of 6 months.

  4. Blood concentration of Hemoglobin A1c (HbA1c).

    Blood samples of HbA1c.

    Time frame: Through study completion, an average of 6 months.

  5. Autism Spectrum Screening Questionnaire (ASSQ).

    The ASSQ consists of 27 items and is scored using a likert scale, with the following alternatives: "not true" (0 points), "somewhat true" (1 point) and "certainly true" (2 points).

    Time frame: Through study completion, an average of 6 months.

  6. Pediatric Quality of Life Inventory (PedsQL).

    PedsQL is a questionnaire measuring health-related quality of life in children and adolescents aged 2 to 18 years. It consists of 23 items including physical functioning (8 items), emotional functioning (5 items), social functioning (5 items) and school functioning (5 items). It has a 5-point response scale: "never a problem" (0 points), "almost never a problem" (1 point), "sometimes a problem" (2 points), "often a problem" (3 points), "almost always a problem" (4 points).

    Time frame: Through study completion, an average of 6 months.

  7. Weight.

    Weight measured in kilograms.

    Time frame: Through study completion, an average of 6 months

  8. The Swanson, Nolan, and Pelham Rating Scale (SNAP-IV).

    Screening questionnaire for attention deficit hyperactivity disorder (ADHD) consisting of 26 items rated on a 4-point scale: "not at all" (0 points), "just a little" (1 point), "quite a bit" (2 points) and "very much" (3 points).

    Time frame: Through study completion, an average of 6 months.

  9. Refraction.

    Visual refraction measured with an autorefractor (Topcon).

    Time frame: Through study completion, an average of 6 months.

  10. Height.

    Height measured in meters.

    Time frame: Through study completion, an average of 6 months.

07

Study locations

1 site
  • Institute of neuroscience and physiology
    Gothenburg, Västra Götaland County SE-413 45, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Oct 2021, 23 months.

Of 360 non-industry observational studies under Premature Birth, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 64. This study's 23 months is below that.

Counting every sponsor, half of 377 studies reached it within 32 months; a quarter within 16 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Dec 9, 2019
StartActual
Oct 28, 2019
Primary completionActual
Oct 1, 2021
CompletionActual
Oct 1, 2021
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04190147
Responsible party
Sponsor
First posted
Dec 9, 2019
Start date
Oct 28, 2019
Primary completion
Oct 1, 2021
Completion
Oct 1, 2021
Last update
May 6, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion